Cardiogenic Shock

Global Cardiogenic Shock Market Is Expanding At A CAGR Of 6.2% By 2032


Cardiogenic Shock Market Outlook (2022-2032)

The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032, expanding at a CAGR of 6.2% over the 2022-2032 time frame.

As per detailed industry analysis by Fact.MR, a market research and competitive intelligence provider, the drugs segment, under treatment type, dominated the global cardiogenic shock market in 2021 in terms of revenue and market share, accounting for 52.7% of the total market, and is expected to surge ahead at a CAGR of 7.8% over the forecast period (2022-2032).

Request Sample

Key Segments Covered in Cardiogenic Shock Industry Research

  • Cardiogenic Shock Market by Treatment Type :

    • Cardiogenic Shock Treatment Drugs
      • Inotropic Agents
      • Thrombolytic
      • Vasopressors
      • Norepinephrine
      • Epinephrine
      • Vasopressin
      • Phenylephrine
      • Dobutamine
    • Antiplatelet medication
    • Other blood-thinning medications
    • Cardiogenic Shock Treatment Devices
    • Mechanical Circulatory Support (MCS) devices
      • Intravascular Micro axial LVAD
      • Intra-Aortic Balloon Pump (IABP)
      • Axial Flow Pumps
      • Extracorporeal Membrane Oxygenation (ECMO)
      • Artery Bypass Pumps
    • Invasive Ventilation (endotracheal tube)
    • In Vitro Test Kits
    • N-Terminal Pro-B-Type Natriuretic Peptide (NT-ProBNP)
    • Troponin
  • Cardiogenic Shock Market by End User :

    • Hospitals
    • Ambulatory Surgical centers
    • Cardiac Catheterization Labs
    • Office-Based Clinics
  • Cardiogenic Shock Market by Region :

    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia
    • Oceania
    • Middle East and Africa (MEA)

Competitive Landscape

Key manufacturers of cardiogenic shock treatment products are actively focusing on the expansion of their portfolios by introducing new products that are technologically advanced, as a strategy to maintain their position in the global cardiogenic shock market

  • In August 2021, the U.S. FDA approved the expansion of the peripheral artery disease (PAD) indication for Xarelto™ plus aspirin.

Similarly, recent developments related to companies operating in the cardiogenic shock market have been tracked by the team at Fact.MR, which are available in the full report.

Leave a Reply

Related Posts